1 min read
Eloxx Pharmaceuticals Posts $0.49 Q3 GAAP Loss Per Share, Beats Estimate
Cash and cash equivalents were $56.3 million on Sept. 30, down from $62 million on June 30. The company said it believes its cash can fund operations into 2028.

Eloxx Pharmaceuticals’ cash and cash equivalents fell to $56.3 million by Sept. 30, while its third-quarter loss per share came in 9 cents better than estimated.
GAAP earnings per share was a loss of $0.49 for the quarter. Cash and cash equivalents totaled $62 million on June 30.
Eloxx said it believes its cash and cash equivalents will be sufficient to fund operations into 2028.